Central Nervous System Cancers

Burt Nabors(University of Alabama at Birmingham), Mario Ammirati(The Ohio State University), Philip J. Bierman(University of Nebraska–Lincoln), Henry Brem(Johns Hopkins University), Nicholas Butowski(University of California, San Francisco), Marc C. Chamberlain(Seattle Cancer Care Alliance), Lisa M. DeAngelis(Memorial Sloan Kettering Cancer Center), Robert A. Fenstermaker(Roswell Park Comprehensive Cancer Center), Allan H. Friedman(Duke Cancer Institute), Mark R. Gilbert(The University of Texas MD Anderson Cancer Center), Deneen Hesser(American Brain Tumor Association), Matthias Holdhoff(Johns Hopkins University), Larry Junck(University of Tennessee Health Science Center), Ronald Lawson(Harvard University Press), Jay S. Loeffler(Vanderbilt University), Moshe Maor(The University of Texas MD Anderson Cancer Center), Paul L. Moots(City Of Hope National Medical Center), Tara Morrison(Northwestern University), Maciej Mrugala(Seattle Cancer Care Alliance), Herbert B. Newton(The Ohio State University), Jana Portnow(Stanford University), Jeffrey Raizer(University of Utah), Lawrence D. Recht(Washington University in St. Louis), Dennis C. Shrieve(University of South Florida), Allen K. Sills(University of Michigan–Ann Arbor), David Tran(Fox Chase Cancer Center), Nam Tran(University of California, San Francisco), Frank D. Vrionis(The Ohio State University), Patrick Y. Wen(University of Alabama at Birmingham), Nicole R. McMillian, Maria Ho(Memorial Sloan Kettering Cancer Center)
Journal of the National Comprehensive Cancer Network
September 1, 2013
10.6004/jnccn.2013.0132
Cited by 250Open Access
Full Text

Abstract

Primary and metastatic tumors of the central nervous system are a heterogeneous group of neoplasms with varied outcomes and management strategies. Recently, improved survival observed in 2 randomized clinical trials established combined chemotherapy and radiation as the new standard for treating patients with pure or mixed anaplastic oligodendroglioma harboring the 1p/19q codeletion. For metastatic disease, increasing evidence supports the efficacy of stereotactic radiosurgery in treating patients with multiple metastatic lesions but low overall tumor volume. These guidelines provide recommendations on the diagnosis and management of this group of diseases based on clinical evidence and panel consensus. This version includes expert advice on the management of low-grade infiltrative astrocytomas, oligodendrogliomas, anaplastic gliomas, glioblastomas, medulloblastomas, supratentorial primitive neuroectodermal tumors, and brain metastases. The full online version, available at NCCN. org, contains recommendations on additional subtypes.

Related Papers

No related papers found

Powered by citation graph analysis